List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
26 August 2014 | By AstraZeneca
AstraZeneca announced that it has entered into a collaboration with gene sequencing company, Illumina, Inc., to develop its next generation sequencing platform for companion diagnostic tests applicable across AstraZeneca’s oncology portfolio...
19 August 2014 | By AstraZeneca
AstraZeneca announced positive top-line results from RECLAIM-1 and RECLAIM-2, the pivotal Phase III studies investigating the potential of the antibiotic ceftazidime-avibactam (CAZ-AVI) as a treatment for hospitalised adult patients with complicated intra-abdominal infections...
14 August 2014 | By AstraZeneca
AstraZeneca announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm...
14 August 2014 | By AstraZeneca
AstraZeneca announced positive top-line results from CLEAR1, CLEAR2 and CRYSTAL, the pivotal Phase III clinical trials investigating the potential of lesinurad...
30 July 2014 | By AstraZeneca
AstraZeneca announced that it has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion...
28 July 2014 | By AstraZeneca
AstraZeneca announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291...
22 July 2014 | By AstraZeneca
AstraZeneca announced that MedImmune has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies...
18 July 2014 | By AstraZeneca
AstraZeneca revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK...
26 June 2014 | By AstraZeneca
AstraZeneca today announced that the US Food and Drug Administration Oncologic Drugs Advisory Committee voted 11 to 2 that current evidence from clinical studies does not support an accelerated approval for use of olaparib...
12 June 2014 | By AstraZeneca
Phase IIa clinical study to commence in patients with severe asthma...
12 June 2014 | By Amgen
Phase 3 program underway to further assess Brodalumab as potential treatment for people living with psoriatic arthritis...
3 June 2014 | By AstraZeneca
AstraZeneca announced that the US Food and Drug Administration has designated its novel investigational drug AZD0914 as a Qualified Infectious Disease Product...
3 June 2014 | By AstraZeneca
AstraZeneca provided an update on the rapid development of its oncology pipeline at a briefing for analysts and investors...
2 June 2014 | By AstraZeneca
As part of the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), Dr Joyce Liu presented data on a Phase II study conducted by the American National Cancer Institute...
20 May 2014 | By AstraZeneca
The Board of AstraZeneca PLC notes the announcement by Pfizer Inc. of its final proposal, comprising £24.76 in cash (45%) and 1.747 Pfizer shares (55%) per AstraZeneca share, representing a value of £55.00 per AstraZeneca share (based on the closing price of Pfizer shares on 16 May 2014...
